A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 30, 2012, Pages 12207-12212

  Baud'huin, Marc ^a   Solban, Nicolas ^b   Cornwall Brady, Milton ^b   Sako, Dianne ^b   Kawamoto, Yoshimi ^b   Liharska, Katia ^b   Lath, Darren ^a   Bouxsein, Mary L ^c   Underwood, Kathryn W ^b   Ucran, Jeffrey ^b   Kumar, Ravindra ^b   Pobre, Eileen ^b   Grinberg, Asya ^b   Seehra, Jasbir ^b   Canalis, Ernesto ^d   Pearsall, R Scott ^b   Croucher, Peter I ^a,e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Acceleron Pharma Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anabolic; Therapy

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; DICKKOPF 1 PROTEIN; ESTROGEN; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SOLUBLE BONE MORPHOGENETIC PROTEIN RECEPTOR 1A FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE STRENGTH; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN DEFICIENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDIATOR; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE RESORPTION; CHROMATOGRAPHY, GEL; CLONING, MOLECULAR; DENSITOMETRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUCIFERASES; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

MUS;

EID: 84864353942     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204929109     Document Type: Article

References (36)

1. Wozney JM (1989) Bone morphogenetic proteins. Prog Growth Factor Res 1:267-280.
2. Massagué J (1992) Receptors for the TGF-beta family. Cell 69:1067-1070.
3. Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD (2004) Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 11:481-488. (Pubitemid 38568954)
4. Hatta T, et al. (2000) Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers 55:399-406. (Pubitemid 32246524)
5. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233-241. (Pubitemid 40136452)
6. Kang Q, et al. (2004) Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11:1312-1320. (Pubitemid 39213996)
7. Gautschi OP, Frey SP, Zellweger R (2007) Bone morphogenetic proteins in clinical applications. ANZ J Surg 77:626-631. (Pubitemid 47063348)
8. Davis S, Miura S, Hill C, Mishina Y, Klingensmith J (2004) BMP receptor IA is required in the mammalian embryo for endodermal morphogenesis and ectodermal patterning. Dev Biol 270:47-63. (Pubitemid 38596928)
9. Mishina Y, et al. (2004) Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem 279: 27560-27566. (Pubitemid 38812597)
10. Kamiya N, et al. (2008) Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 23:2007-2017.
11. Kamiya N, et al. (2010) Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 25:200-210.
12. Okamoto M, et al. (2011) Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26:2511-2522.
13. Fukuda T, et al. (2009) Constitutively activated ALK2 and increased SMAD1/5 co-operatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 284:7149-7156.
14. Shore EM, et al. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525-527.
15. Kamiya N, Kaartinen VM, Mishina Y (2011) Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1. Biochem Biophys Res Commun 414:326-330.
16. Wingerter S, Tucci M, Bumgardner J, Benghuzzi H (2007) Evaluation of short-term healing following sustained delivery of osteoinductive agents in a rat femur drill defect model. Biomed Sci Instrum 43:188-193. (Pubitemid 46668206)
17. Winnier G, Blessing M, Labosky PA, Hogan BL (1995) Bone morphogenetic protein-4 is required for mesodermformation and patterning in the mouse. Genes Dev 9:2105-2116.
18. Zhang H, Bradley A (1996) Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122:2977-2986. (Pubitemid 26371964)
19. Seeherman HJ, Li XJ, Bouxsein ML, Wozney JM (2010) rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 92:411-426.
20. Dewulf N, et al. (1995) Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology 136:2652-2663.
21. Mishina Y, Suzuki A, Ueno N, Behringer RR (1995) Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 9:3027-3037. (Pubitemid 26018138)
22. Mao B, et al. (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321-325. (Pubitemid 32467039)
23. Brott BK, Sokol SY (2002) Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 22:6100-6110. (Pubitemid 34857830)
24. Tian E, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494. (Pubitemid 38010074)
25. Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71.
26. Mukhopadhyay M, et al. (2001) Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 1:423-434. (Pubitemid 33586091)
27. Grotewold L, Rüther U (2002) The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 21:966-975. (Pubitemid 34206169)
28. Okamoto M, Murai J, Yoshikawa H, Tsumaki N (2006) Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 21:1022-1033. (Pubitemid 43962831)
29. Canalis E, Parker K, Zanotti S (2012) Gremlin1 is required for skeletal development and postnatal skeletal homeostasis. J Cell Physiol 227:269-277.
30. Canalis E, Brunet LJ, Parker K, Zanotti S (2012) Conditional inactivation of noggin in the postnatal skeleton causes osteopenia. Endocrinology 153:1616-1626.
31. Bouxsein ML, et al. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468-1486.
32. Glatt V, Canalis E, Stadmeyer L, Bouxsein ML (2007) Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197-1207. (Pubitemid 351339702)
33. Leung CK, Lam FK (1996) Performance analysis for a class of iterative image thresholding algorithms. Pattern Recognit 29:1523-1530. (Pubitemid 126382133)
34. Ridler TW, Calvard S (1978) Picture thresholding using an iterative selection method. IEEE Trans Syst Man Cybern 8:630-632. (Pubitemid 8623043)
35. Heath DJ, et al. (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425-436.
36. Pearsall RS, et al. (2008) A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105:7082-7087. (Pubitemid 351754533)